Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug B007 aims to tame pemphigus with fewer meds

NCT ID NCT06454357

Disease control Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and researchers will track how well the disease is controlled and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
B007 (a drug given as a subcutaneous injection)
What this could lead to
If successful, B007 could offer a new treatment option that helps people with pemphigus achieve remission with less medication.
What could go wrong
This is an early combined phase II/III trial with only 132 participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects who voluntarily participate in this study and sign informed consent form; 2. Subjects who meet the clinical manifestations of pemphigus and are clinically diagnosed as prescribed diseases; 3. Subjects with first diagnosis or relapse; 4. Subjects who have the ability to follow the study protocol as determined by the investigator. Exclusion Criteria: 1. Subjects diagnosed with prescribed diseases; 2. Since the diagnosis of pemphigus, Disease duration\>4 years; 3. Subjects using prescribed drugs; 4. Presence of a specified disease or history of disease; 5. The subjects has prescribed examination abnormalities that are assessed as unsuitable for participation in the study by the investigator; 6. A history of severe allergy or allergic reaction to human or mouse monoclonal antibodies; known contraindications to orally prescribed drugs; 7. Subjects who participate in another interventional clinical trial at a specified time before randomization; 8. Subjects who received live vaccine at the specified time before the first dose and are expected to receive the vaccine at the specified time after the last dose; 9. Pregnant and lactating women; 10. Fertile female subjects do not agree to use effective contraception from signing the informed consent form to the prescribed time after the last dose. Women who are considered fertile by the investigator must have negative serum pregnancy tests before starting the drug; 11. Sexually active male subjects who do not intend to use an effective contraceptive method during the trial period or within specified time after the last dose, or male subjects who plan to donate sperm at a specified time during the trial or after the last dose. 12. Other conditions deemed unsuitable for participation in this study by the researchers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pemphigus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pemphigus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pemphigus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chengdu Second People's Hospital

    RECRUITING

    Chengdu, China

  • Dermatology Hospital of Southern Medical University

    RECRUITING

    Guangzhou, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, China

  • Henan Provincial People's Hospital

    RECRUITING

    Zhengzhou, China

  • Peking University First Hospital

    RECRUITING

    Beijing, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, China

  • Shandong First Medical University-Affiliated Skin Hospital

    RECRUITING

    Jinan, China

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, China

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, China

  • The Second Xiangya Hospital of Central South University

    RECRUITING

    Changsha, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, China

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.